What is a stock summary page? Click here for an overview.
Business Description
Hemogenyx Pharmaceuticals PLC
ISIN : GB00BQVXM815
Description
Hemogenyx Pharmaceuticals PLC is an operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technology has the motive to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation/Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.59 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.91 | |||||
| Debt-to-EBITDA | -0.66 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.5 | |||||
| 3-Year EPS without NRI Growth Rate | -6.3 | |||||
| 3-Year FCF Growth Rate | -5.1 | |||||
| 3-Year Book Growth Rate | 5.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.24 | |||||
| 9-Day RSI | 23.64 | |||||
| 14-Day RSI | 25.3 | |||||
| 3-1 Month Momentum % | -7.54 | |||||
| 6-1 Month Momentum % | -46.15 | |||||
| 12-1 Month Momentum % | -53.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.38 | |||||
| Quick Ratio | 4.38 | |||||
| Cash Ratio | 2.91 | |||||
| Days Payable | 73.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.4 | |||||
| Shareholder Yield % | -59.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -162.87 | |||||
| ROA % | -79.96 | |||||
| ROIC % | -91.47 | |||||
| 3-Year ROIIC % | -156.07 | |||||
| ROC (Joel Greenblatt) % | -135.18 | |||||
| ROCE % | -84.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.97 | |||||
| Price-to-Tangible-Book | 2.34 | |||||
| EV-to-EBIT | -1.59 | |||||
| EV-to-EBITDA | -1.83 | |||||
| EV-to-FCF | -1.51 | |||||
| Earnings Yield (Greenblatt) % | -62.98 | |||||
| FCF Yield % | -75.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hemogenyx Pharmaceuticals PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil £) | |||
| EPS (TTM) (£) | -2 | ||
| Beta | 0.57 | ||
| 3-Year Sharpe Ratio | 0.03 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 37.78 | ||
| 14-Day RSI | 25.3 | ||
| 14-Day ATR (£) | 0.261034 | ||
| 20-Day SMA (£) | 2.558625 | ||
| 12-1 Month Momentum % | -53.03 | ||
| 52-Week Range (£) | 1.6 - 12 | ||
| Shares Outstanding (Mil) | 3.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hemogenyx Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hemogenyx Pharmaceuticals PLC Stock Events
| Event | Date | Price (£) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hemogenyx Pharmaceuticals PLC Frequently Asked Questions
What is Hemogenyx Pharmaceuticals PLC(LSE:HEMO)'s stock price today?
The current price of LSE:HEMO is £1.80. The 52 week high of LSE:HEMO is £12.00 and 52 week low is £1.60.
When is next earnings date of Hemogenyx Pharmaceuticals PLC(LSE:HEMO)?
The next earnings date of Hemogenyx Pharmaceuticals PLC(LSE:HEMO) is 2025-04-25 Est..
Does Hemogenyx Pharmaceuticals PLC(LSE:HEMO) pay dividends? If so, how much?
Hemogenyx Pharmaceuticals PLC(LSE:HEMO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers